Ryan Krueger

Khalaf named asset management and group as the two most likely M&A areas, stressing a disciplined, high-bar approach.

Tadros said margins would normalize gradually over the 3-to-5-year renewal cycle, not in a single quarter or 2027.

Lyndon detailed Japan growth across life, A&H (up 77%), and annuities. Noted yen/dollar product mix was 50-50 and Korea was up 44%. Expects some moderation given tough comps.

Ramy cited three drivers: seasonal dental utilization, new paid family leave programs with higher upfront claims, and slightly elevated LTD severity. Expects moderation in H2.

Michel Khalaf confirmed Q4 seasonality typical but full year expected well below 12.1% target. Cited belt-tightening directive to teams, $3B+ in technology investments over 5 years, and proprietary MetIQ AI platform blending generative, agentic, and classical AI capabilities.

Lyndon Oliver detailed Japan up 31% from new single premium FX Life and yen variable life products. Korea and China driving rest of Asia up 39%. Expects momentum to continue into Q4 and to exceed full year sales guidance.

John McCallion expects spreads ex-VII stable, with a few bps of Q3 seasonality from wholly-owned hotel real estate investments, reverting to low 100s in Q4. Also flagged Chariot Re launch reducing liability exposures and creating $15-20M short-term RIS earnings headwind.

Lyndon Oliver detailed Japan up 10% H1 driven by new single premium FX product launch and yen strengthening tailwind. Korea up 41% H1 from USD-denominated products leveraging Japan expertise. Expects top end of Asia sales guidance range.

Ramy Tadros explained 2% reported growth masked by participating contract mortality impact and dental repricing actions on 1/1 renewals. Underlying growth ~4%. Expects full year reported to be back in line with 4-7% guidance.

Michel Khalaf emphasized all-weather strategy remains intact with no changes to capital management. Noted focus on controlling discretionary expenses while maintaining strategic growth investments.

Ramy Tadros gave detailed response on strong renewals, dental pricing actions, and persistency. Directly addressed competition and pricing dynamics.

Ramy emphasized the well-established market, strong pipeline, and no material impact from lawsuits on PRT activity.

Kamal explained outflows are concentrated in ~5% of AUM, expects normalization over time, and cited a ~$10B committed-not-funded pipeline.

Kamal attributed fee-rate softness to volatile markets and mix, quantified severance at ~$7 million, and expects stabilization from private markets growth.

Amy noted 58.5% loss ratio driven by group life low frequency and dental pricing plus network optimization flowing through. Group disability consistent with prior quarters. Q2 dental seasonally higher but full year loss ratio expected at low end or slightly below guided range.

Kamal attributed redemptions to concentrated activity in US active equity mutual funds from asset allocation and advisory model changes. Asia had standout $1.1B positive NCF, international clients $1.5B positive. Expects nonaffiliated NCF to improve as redemptions normalize. Pipeline very strong.

Kamal highlighted positive NCF across multiple channels: global institutional, US retail platform, and local managed products in Asia and Latin America. Active ETF AUM grew over $3B in 12 months. Real estate gaining market share with momentum in emerging market fixed income.

Kamal noted transaction and borrower fees showing 10-20% year-over-year improvement as markets unclog but still below long-term potential. Longer term performance fees expected to tick up. Deanna emphasized 5% management fee growth as the durable momentum driver.

Kamal detailed US outflows from active rebalancing away from REITs and small cap plus reallocation into nontraditional assets. International clients very strong with $10B quarterly sales up 50% year over year. Asia institutional approaching $50B AUM with sovereign wealth fund wins.

Amy noted dental still competitive on new sales but competitor renewal rates rising which may create opportunity in late 2025 into 2026. Principal prioritizing right upfront pricing over volume. Dental loss ratio improved 50bp in quarter. Seasonal pattern means second half markedly better.

Chris confirmed no significant increase in loans or hardship withdrawals. Participant withdrawal rate stabilized. Dollar amounts up in line with higher average account values.

Kamal highlighted net revenue rate increasing substantially on new mandates, RFP activity at 40% of annual run rate in Q1, and increased business-now vs business-later activity.

Chris noted significant opportunity but cited regulatory hurdles and liquidity challenges. Expects privates packaged in target dates or managed accounts first.

Deanna and Kamal addressed reform positives (DC system reaffirmation, reduced costs) but noted it will take time. Direct, balanced response.

Sullivan reaffirmed the go-forward footprint is global retirement, global asset management, and select US insurance (Group and Individual Life), with Japan a key part rotating toward retirement.

Del Frias pointed to scaling capital-light and fee-based businesses like PGIM to lift free cash flow generation and capital efficiency, but did not quantify a conversion target.

Del Frias confirmed no update to $1.65B corporate expense guidance, noting $70M of one-timers in Q1 with lighter first half and heavier second half expected.

Del Frias explained POJ impact is not linear and grows through the year, but 90% in-force earnings provide resilience. Also noted $50 million total prepays benefiting results episodically.

Andy broadened beyond VA to other areas. 60%+ reduction achieved. Healthy transaction market with plenty of capital and counterparties. Will continue assessing opportunities without providing specifics.

Andy confirmed partnership off to good start. Phase 1: distributing Dai-ichi's cancer product through Life Planners, managing material assets including private credit approaching $1B. Regular CEO-to-CEO meetings. Menu of expansion items but earning trust through execution first.

Andy noted small-end volume remained strong while jumbo space quieter. Key driver is macro uncertainty/volatility. Litigation potentially having some impact. $3T untransacted liabilities and 105% funded status support long-term outlook.

Andy explained move from 20-year-old multi-manager model to one PGIM. Combining public/private credit, collapsing 5 sales forces to 1. Will help drive towards top end of 25-30% margin target faster through expense efficiency and cross-sell revenue.

Andy framed capital deployment as a continuous discipline, stating uses could evolve over time as markets change, but declined to get specific about any planned changes.

Andy acknowledged Q1 margins were disappointing due to seasonal comp expenses and volatility hitting seed/co-investments. Cited three paths to 30%: J-curve investments bearing fruit, recovering real estate/fixed income markets, and expense discipline.

Yanela gave broad response about balancing financial strength, business investment, and shareholder returns without specific allocation details.

Caroline strongly defended PRT industry, noting strong funded statuses and favorable market conditions supporting continued active pipeline.

Brad Dyslin detailed the switch-trade strategy that harvested FX gains to offset losses on lower-yielding bonds and signaled a large ongoing opportunity from the higher-rate environment.

Max Broden explained there is no fixed mix limit, that first sector is under 20% of in-force, and the driver is risk-adjusted return, with Koide reinforcing the strategic role of Tsumitasu in reaching younger customers.

Max indicated Japan reinsurance could become material, citing AA rating advantage, market expertise, and balance sheet diversification benefits from mortality/longevity/spread risk.

Max detailed three drivers: underlying experience trends, net premium ratio mix, and lapsation mix effects. Confirmed confidence in full-year 60-63% range.

Max confirmed 64-66% range still appropriate with tailwinds from 130bp lower net premium ratio and mix shift toward third sector. Expects to start at high end and trend lower throughout forecast period.

Max confirmed no change in M&A philosophy. Virgil noted focus remains on scaling life/disability and dental platforms. Max added niche businesses make both finding and integrating acquisitions difficult.

Yoshizumi attributed strong performance to Miraito's flexible protection design, Yorisou Cancer Consultation Service, and positive results across all channels.

Brad detailed NII drivers: alternatives seasonality, make-whole call, accelerated deployment at attractive spreads, and JGB switch trades. Optimistic on solid Q3 but cautioned about variability.

Max detailed economic hedge components: $2.7B forward contracts at Inc, $4.4B yen debt, plus future higher dividends in dollar terms from Japan offsetting other FX impacts.

Brief but direct confirmation that Q2 should see meaningful positive cancer sales impact from full Miraito launch across all channels.

Kalmbach said the Q3 in-force cession balances Bermuda new-business capacity but yields no 2026 capital benefit and only partial benefit in 2027, emerging over the 3-5 year plan.

Kalmbach tied the raised remeasurement gains to improved morbidity at AIL, Family Heritage and Liberty National, framing higher Liberty cancer claims as a fluctuation, not a trend.

Q4 seasonality offsets net premium ratio benefit. Changes from assumption updates are relatively small incremental adjustments. Normalized margin settling around 41%, obligation ratio improvements offset by rising DAC amortization from American Income renewal commissions. Stable at this level going forward.

Admin expenses stable at 7.3% of premium. NII growth ~3%, required interest ~4%. Financing costs expected down slightly from floating rate exposure. Buybacks assumed at $600-700M minus $85M dividends, spread evenly.

Confirmed 2027 start for Bermuda benefits. Better timing clarity expected after Q3 business plan finalization.

Confirmed ~60% FCF conversion target aligns with Bermuda strategy. Provides parent flexibility for capital management and returning excess to shareholders.

Unchanged at $785-835M. Run rate going forward estimated at $500-600M (midpoint) after one-time reinsurance and valuation manual benefits roll off.

Described a spectrum of adviser succession, growth and remote-advisory (PWG) programs as more profitable and retention-focused, but kept the impact qualitative.

Jim reported very positive early traction with Signature Wealth. Getting both new assets and conversions from other Wrap programs. Described it as one of their best product launches.

Jim noted third-party money market rates still around 3.25%, not enough to drive fundamental reallocation. Expects adjustments as people rethink markets and fixed income over time.

Jim said no change in the flow picture so far. Some days clients are concerned, some see opportunity. Ameriprise keeps them focused on long-term investing.

Walter indicated consolidated G&A roughly flat for the full year, balancing transformation savings against activity growth and continued investments.

Jim indicated flow trends look consistent but cautioned January is difficult to extrapolate. No fundamental change seen but too early for quarterly call.